Can You Take Zoloft While Pregnant?

Sertraline (sold as Zoloft) is one of the most commonly prescribed antidepressants during pregnancy, and most clinical guidelines consider it a first-line option when medication is needed for moderate-to-severe depression or anxiety in pregnant women. That does not mean it is risk-free. Research links first-trimester use to a small increase in certain heart defects, and use later in pregnancy can cause short-lived withdrawal-like symptoms in newborns. But untreated depression carries its own set of pregnancy risks, which is why the real question is rarely “is sertraline safe?” and more often “what creates the least harm for both mother and baby?”

What Untreated Depression Does to a Pregnancy

The risks of sertraline during pregnancy cannot be evaluated in isolation. Depression itself is not a neutral baseline. A systematic review found that maternal depression during pregnancy is associated with preterm birth, low birth weight, stillbirth, increased operative delivery, and higher rates of postpartum depression.¹ A separate retrospective study of over 200,000 pregnancies found that women with depression alone, even without medication, had about a 25% higher risk of severe neonatal illness or death and similar increases in preterm birth and intensive-care admissions compared to women without depression.²

This matters because when studies report that sertraline users have slightly worse outcomes than the general population, part of that gap may reflect the depression itself rather than the drug. Researchers call this “confounding by indication,” and it haunts nearly every observational study in this area.

How Much Sertraline Reaches the Baby

Sertraline does cross the placenta, but less of it gets through than with several other antidepressants. A pharmacokinetic study of pregnant women measured the ratio of drug concentration in umbilical cord blood versus maternal blood, and found that fetal levels of sertraline were roughly a third of the mother’s levels. The breakdown product of sertraline (desmethylsertraline) crossed at a slightly higher rate but still stayed well below maternal concentrations.³ A separate study of infant plasma confirmed that concentrations in newborns were about 25% of the mother’s.⁴

An experimental placental-perfusion study compared how three common SSRIs cross human placental tissue. Sertraline had the lowest transfer rate at about 33%, compared to roughly 43% for paroxetine and 48% for escitalopram.⁵ This relatively low transfer rate is one reason sertraline became a preferred SSRI for use in pregnancy.

First-Trimester Use and Birth Defects

The first trimester is when major organ systems form, so this is the period when any teratogenic risk matters most. A meta-analysis pooling twelve cohort studies found that first-trimester sertraline use was linked to about a 36% increase in the odds of cardiovascular-related malformations, particularly atrial and ventricular septal defects (small holes between the chambers of the heart).⁶ A separate large study of nearly 18,500 pregnancies confirmed a similar increased risk for septal defects and also flagged a possible link to craniosynostosis, a condition where skull bones fuse prematurely.⁷

These numbers sound alarming in relative terms, but the absolute risk is tiny. Septal defects occur in roughly 1 in 100 to 1 in 200 live births in the general population. A 36% relative increase would move that to perhaps 1.3 to 1.4 per 100 to 200 births. Most small septal defects close on their own without treatment. The meta-analysis found no significant increase in malformations of the nervous system, digestive system, or musculoskeletal system with sertraline.⁸

A systematic review of meta-analyses that compared different SSRIs found that sertraline had no evidence of increasing the risk of major congenital malformations overall, unlike paroxetine and fluoxetine, which did. Sertraline was linked to congenital heart defects specifically, but the overall malformation profile appeared more favorable than that of paroxetine.⁹

The Confounding Problem

Here is where the evidence gets genuinely difficult to interpret. Women who take sertraline during pregnancy are not the same population as women who do not. They tend to have more severe mental illness, more stress, different health behaviors, and sometimes different genetic risk profiles. Studies try to adjust for these factors statistically, but they cannot capture everything.

A large Nordic study of over 2.3 million births illustrates this perfectly. In standard analyses comparing SSRI-exposed to unexposed pregnancies, SSRI use was associated with a 13% increase in major birth defects and a 15% increase in cardiac defects. But when the researchers used a sibling design, comparing children born to the same mother where one pregnancy was SSRI-exposed and another was not, those associations disappeared entirely.¹⁰ The implication is that what looked like a drug effect may actually reflect family-level factors: genetics, environment, and the underlying psychiatric condition itself.

A review specifically examining confounding by indication in SSRI research listed birth defects among outcomes where the apparent drug risk may be inflated by the illness being treated.¹¹ This does not prove sertraline is completely harmless. But it means the modest risk signals from observational studies should be treated with some caution, as they likely overstate the drug’s direct contribution.

Risks in the Second Half of Pregnancy

Later in pregnancy, two concerns become relevant: persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome.

PPHN is a rare condition where a newborn’s blood vessels in the lungs fail to relax properly after birth, making breathing difficult. An early landmark study published in the New England Journal of Medicine found that SSRI exposure after the 20th week of pregnancy was associated with about six times the odds of PPHN, while exposure before week 20 carried no increased risk.¹² A later study adjusting for maternal depression specifically reported about four times the odds with SSRI use during the second half of pregnancy.¹³ The relative risk sounds high, but PPHN affects only about 1 to 2 per 1,000 births in the general population, so even a fourfold increase means the absolute risk remains low.

Among individual SSRIs, sertraline appears to carry the lowest PPHN risk. A network meta-analysis that ranked SSRIs by their likelihood of causing PPHN placed sertraline as the least risky, with a probability score of 83% for being the safest option in its class.¹⁴

Neonatal Adaptation Syndrome

About a quarter to a third of newborns exposed to SSRIs late in pregnancy develop a cluster of symptoms in the first few days of life: jitteriness, irritability, feeding difficulties, and occasionally respiratory issues. This is sometimes called neonatal adaptation syndrome or, more bluntly, neonatal withdrawal. An analysis of the World Health Organization’s global reporting database found that the most common symptoms were respiratory problems, irritability, tremor, and feeding difficulties, with a median duration of about a week.¹⁵

A scoping review described the syndrome as usually mild and self-limiting, with newborns sometimes showing slightly lower initial Apgar scores and brief respiratory irregularity.¹⁶ Most babies recover within days without specific treatment, though the symptoms can be distressing for parents. Hospitals that know about the mother’s medication can monitor the newborn and provide supportive care as needed.

Long-Term Effects on Child Development

One of the biggest worries for pregnant women considering sertraline is whether exposure in the womb could affect their child’s brain development years down the line. The current evidence is largely reassuring, though not entirely clean.

A systematic review examining 18 studies on neurodevelopmental outcomes, including cognition, IQ, motor skills, and language, found no consistent associations with antidepressant exposure after controlling for other factors. Among five studies specifically looking at cognitive performance, none found a significant link between prenatal antidepressant exposure and later cognitive deficits. One of five studies examining IQ scores found a small difference, but this disappeared after adjusting for the mother’s IQ and other variables, suggesting the child’s intellect was predicted by factors other than the medication.¹⁷

One smaller prospective study did find that SSRI-exposed children scored slightly lower on cognition and gross motor development scales at age two and a half, with differences of roughly one point on scaled assessments. However, the motor development gap became nonsignificant after accounting for how severe the mother’s anxiety was during pregnancy.¹⁸ A one-point difference on a developmental scale where the average is 10 is not clinically meaningful for most children, and the study could not fully disentangle the medication from the illness.

What Happens If You Stop

Many women consider tapering off sertraline before or during pregnancy. The decision depends heavily on how severe and recurrent your depression has been. A widely cited study from JAMA found that among women who stopped their antidepressants during pregnancy, 68% relapsed, compared to 26% of those who continued. Women who discontinued relapsed about five times faster.¹⁹

A meta-analysis that broke results down by severity found that the relapse risk was dramatically higher for women with a history of severe or recurrent depression, with more than double the risk if they stopped. For women with milder illness, the difference was not statistically significant.²⁰ This is one of the clearest findings in the field: if your depression has been severe or has come back multiple times, stopping medication during pregnancy carries a substantial risk of relapse, and a relapse during pregnancy is not benign for the pregnancy itself.

Recent data also links discontinuation to postpartum outcomes. A study found that women who stopped their antidepressants during pregnancy, or stopped and then restarted, had about a 14% higher risk of postpartum depression compared to women who continued throughout. For those who stopped entirely, the risk of severe postpartum depression was about a third higher.²¹

Your Body Handles Sertraline Differently During Pregnancy

Pregnancy changes how your body processes sertraline. Blood volume increases, liver enzyme activity ramps up, and the kidneys work harder. The result is that sertraline gets cleared faster. One study found that during the final four weeks of pregnancy, the ratio of sertraline concentration to dose was about 22% lower than it was after delivery, meaning less drug was circulating per milligram taken.²² The same study found that genetics matter too. Women with certain variations in the CYP2C19 liver enzyme saw their drug levels drop by about half during pregnancy, while women with fully functional versions of the enzyme had more stable levels.

A separate study confirmed that drug metabolism accelerated between the 20th week and delivery and then returned to baseline by about 12 weeks postpartum.²³ What this means practically is that some women need a dose increase during pregnancy to maintain the same therapeutic effect, and then a reduction after delivery to avoid side effects. Your prescriber should be monitoring how you feel and may adjust the dose, especially in the third trimester.

Preterm Birth and Fetal Growth

Several studies have looked at whether sertraline affects the timing of delivery or the baby’s size. A population-based study found that women who used antidepressants during pregnancy had about a 20% higher prevalence of preterm birth and low birth weight compared to women who never used them. But when these women were compared to women who had used antidepressants before pregnancy and then stopped, the difference vanished, suggesting the underlying illness played a role.²⁴

Another study found that SSRI users had roughly an 11% preterm delivery rate, versus about 7% for nonusers. Women who stopped SSRIs before the end of the first trimester had a preterm rate identical to nonusers. Those who continued beyond the first trimester had a somewhat higher rate of delivering a smaller-than-expected baby, though the preterm birth difference itself was not statistically significant.²⁵ A third study found that women taking antidepressants delivered at an average of 38.5 weeks, compared to 39.4 weeks for depressed women off medication and 39.7 weeks for healthy controls, and had a preterm rate of about 14%.²⁶ Taken together, there appears to be a modest association between continued SSRI use and earlier delivery, but much of it overlaps with the effects of depression itself.

Why Guidelines Prefer Sertraline

An international review of perinatal depression treatment guidelines found broad agreement: for new episodes of mild-to-moderate depression during pregnancy, psychotherapy (especially cognitive behavioral therapy) should be tried first. For severe depression, antidepressants are recommended, with sertraline as the preferred choice.²⁷ The reasoning is practical: sertraline has the longest track record of use in pregnancy, the lowest placental transfer among common SSRIs, no evidence of increasing overall major malformations, and the lowest PPHN risk within its drug class.

That said, if you are already stable on a different antidepressant and it is working well, many clinicians will not recommend switching to sertraline solely because of pregnancy. Switching medications carries its own risk of relapse during the transition period. The general principle is: if you are already on something that works and the risk profile is acceptable, staying put is usually safer than making a change.

Breastfeeding After Sertraline in Pregnancy

For women who take sertraline through pregnancy, the next question is whether they need to stop for breastfeeding. The answer is generally no. A meta-analysis of infant sertraline levels during breastfeeding found that nearly 90% of samples were below the limit of detection, and there was no significant relationship between maternal dose and what showed up in the infant’s blood.²⁸ A pooled analysis of antidepressant levels in nursing mothers and their infants confirmed that sertraline usually produces undetectable levels in the baby.²⁹

One study of 26 breastfed infants whose mothers took a mean daily dose of 124 mg found that sertraline was detectable in only 18% of infant samples, and no adverse effects were reported.³⁰ Sertraline is widely regarded as a first-line antidepressant for breastfeeding women. The continuity from pregnancy through the postpartum period, without needing to switch medications, is another practical advantage.

Preventing Postpartum Relapse

A small but notable randomized trial tested whether starting sertraline immediately after delivery could prevent postpartum depression in women with a history of the condition. Among women who took sertraline, 7% had a recurrence, compared to 50% of those on placebo. The time to recurrence was also significantly longer in the sertraline group.³¹ While this was a pilot study with a small sample, the effect was dramatic enough that it influenced clinical thinking. For women at high risk of postpartum depression, maintaining or initiating sertraline around delivery is a common strategy.

When Therapy May Be Enough

For women with mild-to-moderate depression, cognitive behavioral therapy can be effective without medication. A randomized trial comparing CBT to sertraline in women with depression found that CBT reduced depression symptoms somewhat more effectively, with a moderate advantage over sertraline at the end of the trial. Sertraline was better at reducing acute anxiety symptoms. Both outperformed the control group.³² For women whose depression is driven more by situational stress or who strongly prefer to avoid medication, structured therapy can be a reasonable first step. The catch is access: therapy requires a trained provider, regular appointments, and time, none of which are easy during pregnancy. If depression is severe, worsening, or accompanied by suicidal thoughts, medication is the faster and more reliable intervention.

Epigenetic Changes and What They Mean

Research into whether prenatal SSRI exposure leaves lasting biological fingerprints is still young. One study found that newborns exposed to SSRIs in utero had changes in DNA methylation patterns at a gene involved in drug metabolism (CYP2E1). Interestingly, the methylation changes were most strongly linked to maternal mood rather than the medication alone, pointing again to the difficulty of separating the drug from the disease. Higher methylation at certain sites was independently associated with increased birth weight, regardless of medication or mood status. The biological significance of these epigenetic shifts for the child’s long-term health remains unknown, and researchers caution against drawing clinical conclusions from these early mechanistic findings.

Understanding that this is an area of active investigation can be helpful context if you encounter alarming headlines about SSRIs “changing your baby’s DNA.” The changes observed so far are subtle, do not correspond to any identified disease, and cannot be separated cleanly from the effects of the depression being treated.